Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.
about
HIV-1 superinfection in women broadens and strengthens the neutralizing antibody responseA Blueprint for HIV Vaccine DiscoveryThe Antibody Response against HIV-1Cellular immune responses and susceptibility to HIV-1 superinfection: a case-control studyAssociation between cellular immune activation, target cell frequency, and risk of human immunodeficiency virus type 1 superinfection.Comprehensive Characterization of Humoral Correlates of Human Immunodeficiency Virus 1 Superinfection Acquisition in High-risk Kenyan Women.Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopesHIV neutralizing antibodies: clinical correlates and implications for vaccines.The role of family planning in achieving safe pregnancy for serodiscordant couples: commentary from the United States government's interagency task force on family planning and HIV service integrationNeutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.Low antibody-dependent cellular cytotoxicity responses in Zambians prior to HIV-1 intrasubtype C superinfectionInfection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virusLow-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP elite controllerCharacterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infectionSuperinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus.Specificity of the autologous neutralizing antibody responseComparison of methods to detect HIV dual infectionHIV-1 subtypes and recombinants in Northern Tanzania: distribution of viral quasispecies.Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in UgandaHIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women.The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.Repressive effect of primary virus replication on superinfection correlated with gut-derived central memory CD4(+) T cells in SHIV-infected Chinese rhesus macaquesMonkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials.An augmented probit model for missing predictable covariates in quantal bioassay with small sample size.The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population.How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa.A critical question for HIV vaccine development: which antibodies to induce?Timing and source of subtype-C HIV-1 superinfection in the newly infected partner of Zambian couples with disparate viruses.HIV-1 Superinfection Resembles Primary Infection.Deciphering Multiplicity of HIV-1C Infection: Transmission of Closely Related Multiple Viral Lineages.The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1Contrasting antibody responses to intrasubtype superinfection with CRF02_AG.HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection.Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccinesFrequency of subtype B and F1 dual infection in HIV-1 positive, Brazilian men who have sex with men.Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies.Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection.Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate.
P2860
Q21090490-CD7FE0E9-BF15-42FC-BA9B-9CEB58CA8916Q26829865-56873AF3-AE14-4031-9F65-A28A9C3DB7B0Q27000889-A1D81839-F2FF-42AA-9EEB-7BED77687ED8Q28256438-5D7A30BD-F4E7-44B9-914C-DDD71443E7EAQ33602772-B62FEA3B-6C18-4E2E-8F47-B07649D93BD4Q33603702-A58BBBAD-D521-4144-BB36-038F1AF23EE8Q33648910-91E7F5C7-D0C3-4C81-A26B-72B7F4570C74Q33703451-71C00A4E-4F6D-4FD9-A62B-F967732AE65DQ33769798-CE3A50D3-4E2E-40F6-83AF-C3D599A1B534Q33807535-4C1F6947-0758-4B9C-8784-B3FC40B96FC0Q34016675-8CC679AF-7056-4993-B47C-DDFC398D7B30Q34120140-B8288C2A-FB52-439F-B092-344E77E179D2Q34182086-B277DF24-7365-4981-820A-2E9B57C7A48AQ34300812-1DD734D0-C91B-4B40-8FB7-31E751C5EA36Q34312037-4C086BFD-38ED-4C89-A663-118270CEDE73Q34415389-DE73CFEF-55CB-4773-9B98-3FFD73A65A8BQ34447788-972B7277-FE68-408C-A347-D17C0643FE72Q34464538-67ECD9A1-B7A8-414D-B264-C913C9D71A32Q34587037-33691052-8D43-4956-A1BD-5D7310039254Q34979376-75C95BF9-69FC-4795-9D30-FC2720677BB0Q34982698-7F27080D-2762-4E58-8EBC-D31FC373B168Q34983902-C50FC841-CC43-4005-8D73-EEFEB5765221Q35049812-2D5978B2-8273-4FA8-BED8-CEE7A6151B46Q35050542-9194349C-73E3-4DE0-A4AF-47E52914D3A2Q35140408-2B0ACFDE-83EF-4DE3-8A87-310A9F746151Q35653703-315155F1-DEDB-4900-ADD0-957DA7EADAAAQ35715634-686F1671-F09F-4176-8D57-041675576604Q35783015-A9E0D794-E530-4BCF-B288-1A78D2DEB9A0Q35950936-C6B655C2-EC21-48C7-B423-FBD8125ABAF4Q35993480-EC70DBE2-878F-4E1C-B6FA-C735E8E2F1ECQ36205668-455F3A2D-B5B5-43FF-9095-0D5CD2264997Q36276632-64F056BD-884C-4514-B494-021C62825485Q36306344-AF5C4A95-70D5-4A45-A15F-0AD5EBBCA3B8Q36334990-00EEEAE0-83C1-4ACE-BFC7-3B099306AC51Q36356350-035044C2-CF43-488B-BAB4-4B7581968B92Q36402861-FDD23F6A-4A8C-40CE-A2F9-CEB7FDDDD0A1Q36702114-A7E739B5-A60F-4117-9E39-7AF984999806Q36760049-DC3C4005-CBF3-4117-96FC-7E808BB969CFQ36763288-EEEB04BC-B809-417F-80E1-293634E422C2Q37110714-710D0CB7-C814-4261-8F38-FAF2FD573DCC
P2860
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Human immunodeficiency virus t ...... utralizing antibody responses.
@en
type
label
Human immunodeficiency virus t ...... utralizing antibody responses.
@en
prefLabel
Human immunodeficiency virus t ...... utralizing antibody responses.
@en
P2093
P2860
P356
P1433
P1476
Human immunodeficiency virus t ...... utralizing antibody responses.
@en
P2093
Bhavna Chohan
Catherine A Blish
Minh-An Nguyen
Nina R Derby
Ozge C Dogan
P2860
P304
12094-12103
P356
10.1128/JVI.01730-08
P407
P577
2008-10-08T00:00:00Z